Arrowstreet Capital, Limited Partnership Editas Medicine, Inc. Transaction History

Arrowstreet Capital, Limited Partnership

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2018 Nov 14, 2018	SELL	$27.65 - $38.39 $200,517 - $278,404	-7,252 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$31.4 - $41.01 $10.7 Million - $14 Million	-340,509 Reduced 97.91%	7,252 $260,000
Q1 2018 May 14, 2018	BUY	$29.84 - $44.08 $5.18 Million - $7.65 Million	173,626 Added 99.71%	347,761 $11.5 Million
Q4 2017 Feb 09, 2018	BUY	$21.89 - $31.34 $3.43 Million - $4.91 Million	156,535 Added 889.4%	174,135 $5.35 Million
Q3 2017 Nov 14, 2017	BUY	$15.81 - $24.01 $278,256 - $422,576	17,600	17,600 $423,000

250

57.1M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $83.9M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Arrowstreet Capital, Limited Partnership, based on Form 13F filings with the SEC.

Stay updated on Arrowstreet Capital, Limited Partnership with notifications on news.